Page 70 - IMO-1-1

Innovative Medicines & Omics Antioxidant nanomedicines for therapies

doi: 10.1371/journal.pone.0065389 doi: 10.1002/adhm.202300069
386. Luo LJ, Nguyen DD, Lai JY. Dually functional hollow ceria 397. Lee Y, Kamada N, Moon JJ. Oral nanomedicine for
nanoparticle platform for intraocular drug delivery: A push modulating immunity, intestinal barrier functions, and gut
beyond the limits of static and dynamic ocular barriers microbiome. Adv Drug Deliv Rev. 2021;179:114021.
toward glaucoma therapy. Biomaterials. 2020;243:119961. doi: 10.1016/j.addr.2021.114021
doi: 10.1016/j.biomaterials.2020.119961 398. Tirosh B, Khatib N, Barenholz Y, Nissan A, Rubinstein A.
387. Del Amo EM, Rimpela AK, Heikkinen E, et al. Transferrin as a luminal target for negatively charged
Pharmacokinetic aspects of retinal drug delivery. Prog liposomes in the inflamed colonic mucosa. Mol Pharm.
Retin Eye Res. 2017;57:134-185. 2009;6(4):1083-1091.
doi: 10.1016/j.preteyeres.2016.12.001 doi: 10.1021/mp9000926

388. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel 399. Xu J, Chu T, Yu T, et al. Design of diselenide-bridged hyaluronic
disease. Annu Rev Immunol. 2010;28(1):573-621. acid nano-antioxidant for efficient ROS scavenging to relieve
colitis. ACS Nano. 2022;16(8):13037-13048.
doi: 10.1146/annurev-immunol-030409-101225
doi: 10.1021/acsnano.2c05558
389. Podolsky DK. Inflammatory bowel disease. N Engl J Med.
2002;347(6):417-429. 400. Zhang C, Wang H, Yang X, et al. Oral zero-valent-
molybdenum nanodots for inflammatory bowel disease
doi: 10.1056/NEJMra020831 therapy. Sci Adv. 2022;8(37):eabp9882.
390. Hoivik ML, Moum B, Solberg IC, et al. Health-related doi: 10.1126/sciadv.abp9882
quality of life in patients with ulcerative colitis after a
10-year disease course: Results from the IBSEN study. 401. Huang Q, Yang Y, Zhu Y, et al. Oral metal-free
Inflamm Bowel Dis. 2012;18(8):1540-1549. melanin nanozymes for natural and durable targeted
treatment of inflammatory bowel disease (IBD). Small.
doi: 10.1002/ibd.21863 2023;19:e2207350.
391. Simmonds NJ, Rampton DS. Inflammatory bowel doi: 10.1002/smll.202207350
disease--a radical view. Gut. 1993;34(7):865-868.
402. Sun W, Chen Y, Wang L, et al. Gram-scale preparation
doi: 10.1136/gut.34.7.865 of quercetin supramolecular nanoribbons for intestinal
392. Hu Y, Chen D, Zheng P, et al. The bidirectional interactions inflammatory diseases by oral administration. Biomaterials.
between resveratrol and gut microbiota: An insight into 2023;295:122039.
oxidative stress and inflammatory bowel disease therapy. doi: 10.1016/j.biomaterials.2023.122039
Biomed Res Int. 2019;2019:5403761.
403. Zhao S, Li YX, Liu QY, et al. An orally administered
doi: 10.1155/2019/5403761 CeO2@montmorillonite nanozyme targets inflammation
for inflammatory bowel disease therapy. Adv Funct Mater.
393. Williet N, Paul S, Peyrin-Biroulet L, Roblin X. Pharmacokinetics 2020;30(45):2004692.
of infliximab and reduction of treatment for inflammatory
bowel diseases. Dig Dis Sci. 2016;61(4):990-995. doi: 10.1002/adfm.202004692
doi: 10.1007/s10620-015-3984-2 404. Liu Y, Cheng Y, Zhang H, et al. Integrated cascade
nanozyme catalyzes in vivo ROS scavenging for anti-
394. Paul S, Moreau AC, Del Tedesco E, et al. Pharmacokinetics inflammatory therapy. Sci Adv. 2020;6(29):eabb2695.
of adalimumab in inflammatory bowel diseases:
A systematic review and meta-analysis. Inflamm Bowel Dis. doi: 10.1126/sciadv.abb2695
2014;20(7):1288-1295. 405. Liu J, Shi L, Wang Y, et al. Ruthenium-based metal-organic
doi: 10.1097/MIB.0000000000000037 framework with reactive oxygen and nitrogen species
scavenging activities for alleviating inflammation diseases.
395. Vargas Robles H, Citalan Madrid AF, Garcia Ponce A, Nano Today. 2022;47:101627.
et al. Experimental colitis is attenuated by cardioprotective
diet supplementation that reduces oxidative stress, doi: 10.1016/j.nantod.2022.101627
inflammation, and mucosal damage. Oxid Med Cell Longev. 406. Wang Q, Cheng C, Zhao S, et al. A valence-engineered
2016;2016:8473242. self-cascading antioxidant nanozyme for the therapy of
doi: 10.1155/2016/8473242 inflammatory bowel disease. Angew Chem Int Ed Engl.
2022;61(27):e202201101.
396. Zhang Y, Wang T, Sun M, et al. Advanced nanomedicine:
Redefining therapeutic paradigms for inflammatory bowel doi: 10.1002/anie.202201101
disease. Adv Healthc Mater. 2023;12:e2300069. 407. Sommer F, Anderson JM, Bharti R, Raes J, Rosenstiel P.

Volume 1 Issue 1 (2024) 64 doi: 10.36922/imo.2527